News

News

November 14, 2019

BioStock-article: Follicum approaches Phase II study with proDERM

BioStock published an article on 14 November 2019 about Follicum, which can be read in full below. Biotech company Follicum will conduct its upcoming Phase II study in hair loss together with the German CRO proDERM. The Charité Universitätsmedizin Berlin had previously been confirmed as a partner for the study, which is expected to start […]

October 22, 2019

BioStock-article: Follicum a step closer to phase II

BioStock published an article on 21 October 2019 about Follicum, which can be read in full below. Today, news broke that Follicum had completed the supplementary toxicology studies that will form the basis for the upcoming phase II trial with their topical formulation of FOL-005. The study results were positive, safeguarding the company’s expectation to initiate […]

September 30, 2019

BioStock-article: FOLLICUM IS CLOSING IN ON PROOF-OF-CONCEPT FOR HAIR LOSS PRODUCT

BioStock published an article on 30 September 2019 about Follicum, which can be read in full below. Follicum’s business strategy is to enter into a partnership, out license or sell their candidates following phase II trials at the latest. With proof-of-concept and top-line-data for FOL-005 firmly within reach during 2020, the company is getting closer […]

September 27, 2019

Interview with Carl Johan Spak, new Member of the Board in Follicum

What is your background and what have you done before joining Follicum? I have been in the pharmaceutical industry for more than 30 years. After some years in ACO and Pharmacia I joined Recip in 1995 when it started its business. With the exception of one year at Meda in 2008, I have been with […]

September 13, 2019

BioStock video interview with Follicum’s CEO Jan Alenfall

This week the yearly event Nordic Life Science Days (NLSDays) took place in Malmö, Sweden. BioStock took the opportunity to talk to Jan Alenfall, the CEO of Follicum, about the status of the company’s projects – hair growth and diabetes. See the interveiw, in English, here. For further information, please contact: Jan Alenfall – CEO, […]

August 15, 2019

Video interview with Follicum’s CEO now published

An interview with Follicum’s CEO Jan Alenfall is now published on the company’s website. To access the video, please click here. For further information, please contact: Jan Alenfall – CEO, Follicum AB Telephone: +46 46 19 21 97 Email: info@follicum.com About Follicum AB Follicum is a biotech company focused on the discovery and development of […]

June 24, 2019

Summer Greetings from Follicum

During spring we have reached two important milestones, one in each project. With regards to the hair project we have submitted a patent application for our unique topical formulation of FOL-005, and in the diabetes project we have chosen a candidate. Preparations for a clinical phase II-study with our unique topical formulation of FOL-005 in […]

June 12, 2019

Interview with Mats Persson, new Member of the Board in Follicum

What is your background and what have you done before joining Follicum? I have more than 35 years of experience in marketing and licensing within the global pharmaceutical industry. Today, I hold the position as Head of Nordic at Tesaro, an American biotech company in oncology, recently acquired by GSK. I have extensive experience from […]

April 24, 2019

Clinical progress of Follicum’s lead candidate FOL-005 for hair growth presented at the world’s largest hair conference

Follicum AB (“Follicum” or “The Company”) today announces that a poster entitled “FOL-005 – modulation of hair growth in clinical studies” will be presented at the 11th World Congress for Hair Research scientific conference in Barcelona, April 24-27, 2019. This conference is one of the most important in the field bringing together the world’s leading […]

February 28, 2019

Endpoints News article about Follicum

On 27 February 2019, Endpoints News published an article about Follicum: “Follicum, a Swedish biotech company born to find a treatment for hair loss, now has diabetes in its crosshairs”. Read the article For further information, please contact: Jan Alenfall – CEO, Follicum AB Telephone: +46 46 19 21 97 Email: info@follicum.com About Follicum AB […]